Search
forLearn
5 / 801 resultslearn HT-B
learn menthol
learn methylsulfonylmethane
learn medium chain triglycerides
Research
5 / 1000+ results
research Cutaneous extramedullary haematopoiesis: Implications in human disease and treatment
Skin can produce blood cells, often due to disease, which might lead to new treatments for skin and blood conditions.
research Successful Treatment of Cutaneous Mast Cell Tumors in Cats Using Electrochemotherapy: A Case Series
Electrochemotherapy successfully treated skin tumors in cats without recurrence.
research ECM1 modified HF-MSCs targeting HSC attenuate liver cirrhosis by inhibiting the TGF-β/Smad signaling pathway
ECM1-modified stem cells can effectively treat liver cirrhosis.
research Neurobehavioral protective properties of curcumin against the mercury chloride treated mice offspring
Curcumin can protect against mercury's harmful effects on brain and behavior.
research CATALASE INTRINSIC EMISSIONS OF ELECTROMAGNETIC FIELDS AS PROBABLE CAUSE IN CANCEROGENESIS FROM CONSUMPTION OF RED AND PROCESSED MEAT
Catalase in processed meats may cause cancer by emitting electromagnetic fields.
Community Join
5 / 1000+ resultscommunity EveryChem 3HP / PP30 page data vs NMR PDFs in their website : metadata mistake or document mismatch?
There is an inconsistency between the molecular weight and formula listed on EveryChem's product page and the analytical PDFs for 3HP and PP30, suggesting a possible error in the product description. Concerns are raised about EveryChem's business practices and lack of transparency in testing and manufacturing.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community Hope Medicine's HMI-115 could be out in 2027 per Company Founder
Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.
community Anyone have experience with GHK-CU
GHK-Cu is being considered for hair growth, but users report mixed results. Some use it alongside other treatments like 5AR inhibitors, making it hard to determine its effectiveness.
community HMI 115 Phase 1 update: Changes to clinicaltrials.gov page
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.